TABLE OF CONTENTS

In This Issue/Research Watch/News in Brief.................................................. 1235

From the IASLC Tobacco Control Committee.............................................. 1241

EDITORIALS

Breathing Life Into Lung Cancer Screening Trials....................................... 1244
Carolyn M. Dresler, MD, MPA, and William K. Evans, MD, FRCPC

About the Cover: the cover image is from Figure 3 in the article by Shigematsu on page 1318.

(continued on next page)
The Pathologic Nodal Staging Quality Gap: Challenge as Opportunity in Disguise..............................................................................................................1247
Raymond Uyiosa Osarogiagbon, M.B.B.S., FACP

CONTROVERSIES IN THORACIC ONCOLOGY

The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era ...............1250
Fieke Hoeijmakers, MD, Wilhelmina H. Schreurs, MD, PhD,
Emile F. I. Comans, MD, PhD, José S. A. Belderbos, MD, PhD,
Pieter E. Postmus, MD, PhD, Rob A. E. M. Tollenaar, MD, PhD, and
David J. Heineman, MD, PhD

The TNM System Is Adequate for Making Treatment Decisions and Prognostication in Lung Cancer.................................................................1255
Ramón Rami-Porta, MD, Raymond U. Osarogiagbon, M.B.B.S., and Hisao Asamura, MD

REVIEW ARTICLE

Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline .........................................1258
Conrad B. Falkson, MbChB., Emily T. Vella, PhD, Peter M. Ellis, M.B.B.S., PhD,
Donna E. Maziak, MDCM, MSc, Yee C. Ung, MD, and Edward Yu, MD, PhD

ORIGINAL ARTICLES

Tobacco Control

Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial...................................................................................................1276
Ugo Pastorino, MD, Vito Ladisa, PharmD, Sara Trussardo, PharmD, Federica Sabia, MSc,
Luigi Rolli, MD, Camilla Valsecchi, MSc, Roberta E. Ledda, MD,
Gianluca Milanese, MD, PhD, Paola Suatoni, MSc, Mattia Boeri, PhD,
Gabriella Sozzi, PhD, Alfonso Marchianò, MD, Elena Munarini, PsyD, Roberto Boffi, MD,
Silvano Gallus, PhD, and Giovanni Apolone, MD

Translational Oncology

Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early Stage NSCLC ............................................1287
Brendan T. Heiden, MD, MPH, Daniel B. Eaton Jr., MPH, Su-Hsin Chang, PhD, SM,
Yan Yan, MD, PhD, Martin W. Schoen, MD, MPH, Mayank R. Patel, MD,
Daniel Kreisel, MD, PhD, Ruben G. Nava, MD, Bryan F. Meyers, MD, MPH,
Benjamin D. Kozower, MD, MPH, and Varun Puri, MD, MSCI

Non-Small Cell Lung Cancers

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study..............................................................................................1297
Yuankai Shi, MD, Gongyan Chen, MD, Xiang Wang, MM, Yunpeng Liu, MD, Lin Wu, MD,
Yanrong Hao, MD, Chunling Liu, MM, Shuyang Zhu, MM, Xiaodong Zhang, BMed,
Yuping Li, MM, Jiwei Liu, MD, Lejie Cao, MM, Ying Cheng, MD, Hui Zhao, BMed,
Shucai Zhang, MD, Aimin Zang, MM, Jiwei Cui, MD, Jian Feng, MM, Nong Yang, MD,
Fei Liu, MM, Yong Jiang, MSc, and Chuan Gu, MM

(continued on next page)
TABLE OF CONTENTS (continued)

**OPEN ACCESS** Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study ..............................................................................................1306
Yuankai Shi, MD, Shimian Wu, MD, Ke Wang, MD, Shundong Cang, MD, Wenzhuo Yao, MD, Yun Fan, MD, Lin Wu, MD, Meijuan Huang, MD, Xingya Li, MD, Yueyin Pan, MD, Zhihong Yang, MD, Bo Zhu, MD, Gongyan Chen, MD, Jianhua Shi, MD, Meili Sun, MD, Jian Fang, MD, Lijun Wang, MD, Zhaohong Chen, MD, Chunling Liu, MD, Jingzheng Li, MD, Jiwei Liu, MD, Shenghua Sun, MD, Yanqiu Zhao, MD, Yanzhen Guo, MD, Zili Meng, MD, Zhefeng Liu, MD, Zhigang Han, MD, Hong Lu, MD, Rui Ma, MD, Sheng Hu, MD, Guofang Zhao, MD, Zheng Liu, MD, Congying Xie, MD, Diansheng Zhong, MD, Hui Zhao, MD, Huqing Yu, MD, Longzhen Zhang, MD, Minghong Bi, MD, Shanyong Yi, MD, Shuliang Guo, MD, Tianan Yi, MD, Wen Li, MD, Yinqing Lin, MD, Yongqian Shu, MD, Zhenlong Chen, MD, Zhongliang Guo, MD, Michael Greco, PhD, Tingting Wang, MSc, and Haijiao Shen, MBA

**IMAGE OF THE MONTH**

EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma ................................................................................................ 1318
Yasuyuki Shigematsu, MD, PhD, Kaoru Nakano, MD, Ken Uchibori, MD, PhD, and Kentaro Inamura, MD, PhD

**LETTERS TO THE EDITOR**

✉ Now We Have the First Animal Model for Thymoma..............................e91
Taichiro Goto, MD, PhD

✉ Reply to Dr. Goto’s Letter: “A Thymoma Mouse Model Harboring a Gtf2i L424H Mutation” .................................................................e92
Yongfeng He, PhD, and Giuseppe Giaccone, MD, PhD

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for re-use or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage: Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions: For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843800 (UK) / (+1) 215 239 3804 (USA).

Author rights: Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorrights).

Notice: The statements and opinions contained in the material herein are solely those of the individual authors and contributors and not those of the International Association for the Study of Lung Cancer or Elsevier Inc. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher or the IASLC for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

For advertising orders and inquiries: North and South America: Courtney Leonard, Elsevier Inc., 230 Park Avenue, New York, NY 10169; phone (212) 633-3874; fax (212) 462-1935; e-mail: reprints@elsevier.com.

Journal Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, and MEDLINE.